Table. Demographics, Classifications, and Outcomes of Patients With Hansen Disease.
| Characteristic | Value |
|---|---|
| Demographics | |
| Patients, No. (%) | |
| Total | 312 |
| Excludeda | 125 (40.1) |
| Included | 187 (59.9) |
| Age at diagnosis, mean (SD) [range], y | 35.7 (12) [7-75] |
| Sex, No. (%) | |
| Male | 130 (69.5) |
| Female | 57 (30.5) |
| Race/ethnicity, No. (%) (n = 171) | |
| Latino | 99 (57.9) |
| Asian | 45 (26.3) |
| Pacific Islander | 11 (6.4) |
| Unknown/other | 14 (8.2) |
| White | 2 (1.2) |
| Country of origin, No. (%) (n = 132) | |
| Mexico | 69 (52.3) |
| Vietnam | 14 (10.6) |
| The Philippines | 13 (9.8) |
| India | 8 (6.1) |
| China | 5 (3.8) |
| Cambodia | 5 (3.8) |
| Otherb | 18 (13.6) |
| Delay in diagnosis (n = 23), median [range] | >3 y [4-6 mo to >10 y] |
| Follow-up duration, mean (SD) [range], y | 22.4 (14.0) [1-45] |
| Leprosy Classification, No. (%) | |
| Ridley-Jopling | |
| Polar lepromatous leprosy | 10 (63.5) |
| Borderline lepromatous leprosy | 41 (24.6) |
| Borderline tuberculoid leprosy | 16 (9.6) |
| Polar tuberculoid leprosy | 2 (1.2) |
| Indeterminate leprosy | 1 (0.6) |
| Mid-borderline leprosy | 1 (0.6) |
| WHO (n = 167) | |
| Multibacillary leprosyc | 148 (88.6) |
| Paucibacillary leprosyd | 19 (11.4) |
| Reactional State, No. (%) | |
| Erythema nodosum leprosum (n = 116) | 86 (74.1) |
| Multibacillary leprosy with erythema nodosum leprosum (n = 86) | 86 (100.0) |
| Paucibacillary leprosy with erythema nodosum leprosum (n = 86) | 0 |
| Delayed-type reversal reaction (n = 116) | 27 (23.3) |
| Multibacillary leprosy with delayed-type reversal reaction (n = 27) | 20 (74.1) |
| Paucibacillary leprosy with delayed-type reversal reaction (n = 27) | 7 (25.9) |
| Lucio reaction (n = 116) | 3 (2.6) |
| Multibacillary leprosy with Lucio reaction (n = 3) | 3 (100.0) |
| Paucibacillary leprosy with Lucio reaction (n = 3) | 0 |
| Neuritis (n = 84) | 31 (36.9) |
| Antibiotics Used, No. (%) | |
| Multibacillary leprosy (n = 147) | |
| 1 | 26 (17.7) |
| 2 | 47 (32.0) |
| 3 | 50 (34.0) |
| 4 | 20 (13.6) |
| >5 | 4 (2.7) |
| Paucibacillary leprosy (n = 19) | |
| 1 | 6 (31.6) |
| 2 | 7 (36.8) |
| 3 | 5 (26.3) |
| 4 | 1 (5.3) |
| >5 | 0 |
| Antibiotics Used in WHO Grade 0 Disability, No. (%)e | |
| Multibacillary leprosy (n = 93) | |
| 1 | 26 (28.0) |
| 2 | 33 (35.5) |
| 3 | 24 (25.8) |
| 4 | 8 (8.6) |
| >5 | 2 (2.2) |
| Paucibacillary leprosy (n = 13) | |
| 1 | 3 (23.1) |
| 2 | 6 (46.2) |
| 3 | 3 (23.1) |
| 4 | 1 (7.7) |
| >5 | 0 |
| Patient Outcome | |
| WHO grade 0 disabilitye | 106 (56.7) |
| WHO grade 1 disabilitye | 30 (16.0) |
| WHO grade 2 disabilitye | 49 (26.2) |
| Death related to Hansen disease | 0 |
Abbreviation: WHO, World Health Organization.
a
Patients were excluded from analysis if they did not have Hansen disease or information was not available in the electronic medical record.
b
Brazil, Cuba, Colombia, El Salvador, Ethiopia, Indonesia, Laos, Malaysia, Thailand, America Samoa, Sri Lanka, United States.
c
More than 6 lesions (mid-borderline leprosy, polar lepromatous leprosy, borderline lepromatous leprosy).
d
One to 5 lesions (indeterminate leprosy, polar tuberculoid leprosy, or borderline tuberculoid leprosy).
e
Grade 0, no signs or symptoms suggestive of leprosy or disability for more than 1 year; grade 1, loss of protective sensation; grade 2, visible deformity.